Utility of galactomannan enzyme immunoassay and (1, 3) β-D-glucan assay in invasive fungal infection

National Medical Journal of China

Volumn 90, Issue 6, 2010, Pages 371-374

  Yu, Jin ^a   Li, Ruo Yu ^a   Gao, Lu Juan ^a   Lu, Qiao Yun ^a   Wang, Xiao Hong ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Diagnosis; Glucans; Mannans; Mycoses; Serologic tests

Indexed keywords

ENDO 1,3 BETA GLUCANASE; GALACTOMANNAN; BETA GLUCAN; MANNAN;

ARTICLE; ENZYME IMMUNOASSAY; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SYSTEMIC MYCOSIS; ADOLESCENT; ADULT; AGED; BLOOD; CHEMISTRY; CHILD; EVALUATION; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; MYCOSIS; PLASMA; PREDICTION AND FORECASTING; SERUM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BETA-GLUCANS; CHILD; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MANNANS; MIDDLE AGED; MYCOSES; PLASMA; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SERUM; YOUNG ADULT;

EID: 84871464916     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2010.06.004     Document Type: Article

References (13)

1. De Pauw B, Walsh T J, Donnelly J P, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis, 2008, 46: 1813-1821.
2. Pfeiffer C D, Fine J P, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis, 2006, 42: 1417-1427.
3. 2007, 87: 83-86.
4. Pickering J W, Sant H W, Bowles C A, et al. Evaluation of a (1→3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol, 2005, 43: 5957-5962.
5. Ostrosky-Zeichner L, Alexander B D, Kett D H, et al. Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis, 2005, 41: 654-659.
6. Pazos C, Ponton J, Del Palacio A. Contribution of (1→3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol, 2005, 43: 299-305.
7. Aubry A, Porcher R, Bottero J, et al. Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders. J Clin Microbiol, 2006, 44: 389-394.
8. Surmont I, Stockman W. Gluconate-containing intravenous solutions: another cause of false-positive galactomannan assay reactivity. J Clin Microbiol, 2007, 45: 1373.
9. Chambon-Pautas C, Costa J M, Chaumete M T, et al. Galactomannan and polymerase chain reaction for the diagnosis of primary digestive aspergillosis in a patient with acute myeloid leukaemia. J Infect, 2001, 43: 213-214.
10. Ogawa M, Hori H, Niiguchi S, et al. False-positive plasma (1→3)-beta-D-glucan test following immunoglobulin product replacement in an adult bone marrow recipient. Int J Hematol, 2004, 80: 97-98.
11. Usami M, Ohata A, Horiuchi T, et al. Positive (1→3)-beta-D-glucan in blood components and release of (1→3)-beta-D-glucan from depth-type membrane filters for blood processing. Transfusion, 2002, 42: 1189-1195.
12. Kato A, Takita T, Furuhashi M, et al. Elevation of blood (1→3)-beta-D-glucan concentrations in hemodialysis patients. Nephron, 2001, 89: 15-19.
13. Digby J, Kalbfleisch J, Glenn A, et al. Serum glucan levels are not specific for presence of fungal infections in intensive care units. Clin Diagn Lab Immunol, 2003, 10: 882-885.